Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1097807

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1097807

Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

PUBLISHED:
PAGES: 76 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3495
PDF (Site License)
USD 6990
PDF (Global License)
USD 10485

Add to Cart

This reports provides a data-driven overview of the current and future competitive landscape in Neuroendocrine tumors therapeutics.

Synopsis

  • In 2022, diagnosed prevalence of Neuroendocrine tumors will reach to 689,000 cases across the 16 countries covered in GlobalData's epidemiology forecast.
  • There are eight leading marketed drugs for the treatment of Neuroendocrine tumors. Pfizer, Novartis, and Hutchison are key players in the disease space.
  • R&D activity in Neuroendocrine tumors space is considerable globally, with 11 products in Phase III development.
  • Academic sponsors dominate clinical trial development in Neuroendocrine tumors, with Germany emerging as the key country for conducting late-stage clinical trials in Neuroendocrine tumors.
  • Deals involving strategic alliances of Neuroendocrine tumors assets are the most common type globally.
  • No commercial launch is expected for Neuroendocrine tumors in the next 18 months.

Scope

GlobalData's Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Neuroendocrine tumors market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine tumors market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Product Code: GDHC064CL

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Overview by Molecule Type
  • 4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

  • 5.1 Late-stage Pipeline Drugs
  • 5.2 Overview by Development Stage
  • 5.3 Overview by Mechanism of Action
  • 5.4 Overview by Route of Administration
  • 5.5 Overview by Molecule Type
  • 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

  • 6.1 Historical Overview
  • 6.2 Overview by Phase
  • 6.3 Overview by Status
  • 6.4 Overview by Phase for Ongoing and Planned Trials
  • 6.5 Trials with Virtual Components
  • 6.6 Geographic Overview
  • 6.7 Single-Country and Multinational Trials by Region
  • 6.8 Top 20 Sponsors with Breakdown by Phase
  • 6.9 Top 20 Sponsors with Breakdown by Status
  • 6.10 Overview by Endpoint Status
  • 6.11 Overview by Race and Ethnicity
  • 6.12 Enrollment Data
  • 6.13 Top 20 countries for Trial Sites
  • 6.14 Top 20 Sites Globally
  • 6.15 Feasibility Analysis - Geographic Overview
  • 6.16 Feasibility Analysis - Benchmark Models

7 Deals Landscape

  • 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

  • 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

  • 10.1 Methodology
  • 10.2 Methodology - PTSR and LoA Analysis
  • 10.3 About the Authors
  • 10.4 Contact Us
  • 10.5 Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!